Last edition
News about "CLDN18.2-positive gastric cancer"
Astellas Doses First Patient in Phase 3 ASP2138 Study for Gastric Cancer
Astellas doses the first patient in its phase 3 ASP2138 study for CLDN18.2-positive, HER2-negative advanced gastric and gastroesophageal junction cancer.
CLDN18.2-positive Gastric Cancer | 26/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members